

Resource Summary Report

Generated by T1D on Sep 5, 2026

Strelka2

RRID:SCR_005109

Type: Tool

Proper Citation

Strelka2 (RRID:SCR_005109)

Resource Information

URL: <https://github.com/Illumina/strelka/>

Proper Citation: Strelka2 (RRID:SCR_005109)

Description: Software for somatic single nucleotide variant (SNV) and small indel detection from sequencing data of matched tumor-normal samples. Strelka2 germline and somatic small variant caller.

Synonyms: Strelka

Resource Type: software resource, source code

Defining Citation: [PMID:22581179](#), [PMID:30013048](#)

Keywords: single nucleotide variant, indel, somatic snv, next-generation sequencing, bio.tools

Related Condition: Cancer, Tumor, Normal

Availability: Free, Available for download, Freely available

Resource Name: Strelka2

Resource ID: SCR_005109

Alternate IDs: biotools:strelka

Alternate URLs: <https://bio.tools/strelka>, <https://sources.debian.org/src/strelka/>

Old URLs:

<http://bioinformatics.oxfordjournals.org/content/early/2012/05/10/bioinformatics.bts271.full.pdf>

License: GNU GPL v3

Record Creation Time: 20220129T080228+0000

Record Last Update: 20260904T000612+0000

Ratings and Alerts

No rating or validation information has been found for Strelka2.

No alerts have been found for Strelka2.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 283 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Yang Q, et al. (2026) Molecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC. Journal of virology, 100(1), e0148725.

Yang W, et al. (2026) Clinically actionable stratification of uncommon MET fusions: a precision oncology framework. Journal of translational medicine, 24(1).

Pregnall AM, et al. (2026) Metastatic progression of pheochromocytoma and paraganglioma occurs via parallel evolution. NPJ precision oncology, 10(1).

Li Q, et al. (2026) Revealing the Potential Associations of Mutation-Related Genes with Lymph Node Metastasis in Gallbladder Cancer Through Transcriptome and Exome Sequencing. Biomedicines, 14(5).

Tirtei E, et al. (2026) Mapping Genomic Heterogeneity in Pediatric and Adolescent-Young Adult Sarcomas: Insights from the Italian SAR-GEN2016 and SAR-GEN_ITA Prospective Multicenter Trials. Cancer research communications, 6(4), 857.

Andersen L, et al. (2026) Cell-Free DNA-Derived Immune Cell Ratios Uncover Cancer-Associated Systemic Changes. Cancer research communications, 6(4), 811.

Wang C, et al. (2026) A Deep Learning-Driven Framework Integrating Organoid-Based Functional Validation Identifies Universal Neoantigens from Recurrent Glioma Mutations. Cancer research, 86(12), 3074.

Bhojnagarwala PS, et al. (2026) synDNA vaccine against TCR chains and neoantigens for T cell lymphoma therapy. Cancer immunology, immunotherapy : CII, 75(3), 80.

Shi Y, et al. (2026) Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in BRAF-Mutant Melanoma. bioRxiv : the preprint server for biology.

Bassiouni R, et al. (2026) Integrated Single-Cell Whole-Genome Sequencing and Spatial Transcriptomics Reveal Intratumoral Heterogeneity in Ovarian Cancer. *Cancer research communications*, 6(5), 1020.

Roush SM, et al. (2026) Mutational profiling of HIV+ diffuse large B-cell lymphoma reveals distinct mutational features with evidence of genomic instability. *AIDS (London, England)*, 40(6), 719.

Adhikary U, et al. (2026) Cancer Susceptibility to Stapled Oncolytic Peptides Is Dictated by Membrane Cholesterol and Inflammatory Signaling. *Cancer research*, 86(11), 2810.

Hao W, et al. (2025) Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review). *International journal of molecular medicine*, 55(1).

Rebello RJ, et al. (2025) Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary. *Nature communications*, 16(1), 4422.

Lu S, et al. (2025) Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia/Ib trial. *EClinicalMedicine*, 84, 103258.

Lu Y, et al. (2025) Intrahepatic Microbial Heterogeneity in Multifocal Hepatocellular Carcinoma and Its Association with Host Genomic and Transcriptomic Alterations. *Cancer discovery*, 15(8), 1630.

Fiorica PN, et al. (2025) Germline Pathogenic DROSHA Variants Are Linked to Pineoblastoma and Wilms Tumor Predisposition. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(8), 1491.

Ishikawa R, et al. (2025) Immunohistochemical and molecular evolutionary features of jejunoileal adenocarcinoma unveiled through comparative analysis with colorectal adenocarcinoma. *Neoplasia (New York, N.Y.)*, 66, 101180.

Lilljebjörn H, et al. (2025) The AML cellular state space unveils NPM1 immune evasion subtypes with distinct clinical outcomes. *Nature communications*, 16(1), 10592.

Wang J, et al. (2025) Potential biomarkers of primary resistance to first- and second-generation EGFR-TKIs in non-small-cell lung cancer: a real-world study. *Therapeutic advances in medical oncology*, 17, 17588359251336632.